Skip to content
GLP-1 Scorecard
Menu

Evidence review

Semaglutide vs. Tirzepatide: What the Trials Show

Compare SURMOUNT-5 head-to-head weight-loss results, older trial limits, side effects and the product and cost questions to discuss with a clinician.

By GLP-1 Scorecard
On this page

Tirzepatide produced greater average weight loss than semaglutide in SURMOUNT-5, a direct comparison of specific weekly injection regimens in adults without diabetes. That is stronger evidence for this question than comparing the headline results of unrelated trials. It still does not establish the best prescription for an individual or the effectiveness of a compounded preparation.5

Start with the clinician's assessment of the actual product and your history. Then compare access, tolerability, continuing cost and follow-up. The trial result is useful evidence for that conversation, not a way to select a prescription from a provider's price table.

The obesity head-to-head: SURMOUNT-5

SURMOUNT-5 randomized 751 adults with obesity or overweight and a weight-related complication, without diabetes. Over 72 weeks, maximum tolerated weekly injections were tirzepatide 10/15 mg or semaglutide 1.7/2.4 mg. Published in 2025, this open-label, Lilly-funded study included diet and activity support.5

Least-squares mean weight change was −20.2% versus −13.7%, a 6.5 percentage-point difference. Gastrointestinal events predominated, usually mild/moderate during escalation. Neither a personal result nor better tolerability is guaranteed.5

Keep the tested dose and formulation attached to the result

SURMOUNT-5 studied those injection regimens. Current Wegovy labeling also includes tablets and a 7.2 mg injection option; they were not the semaglutide treatments compared in this trial. Do not describe its result as a comparison against every current semaglutide formulation or dose.2, 5

Semaglutide acts at the GLP-1 receptor; tirzepatide acts at GIP and GLP-1 receptors. The current product labels describe those pharmacologic differences. They do not make receptor count a personal outcome forecast or prove that dual activity alone explains the trial difference.2, 6

The same product discipline matters when comparing daily liraglutide with weekly semaglutide. A molecule name is only the beginning of a useful comparison.

Why the older trial numbers differ

STEP 1 studied weekly semaglutide 2.4 mg against placebo for 68 weeks in adults with overweight or obesity without diabetes. Mean weight change was −14.9% versus −2.4%. SURMOUNT-1 separately studied weekly tirzepatide for 72 weeks, reporting −15.0%, −19.5% and −20.9% at 5, 10 and 15 mg, versus −3.1% for placebo.1, 3

These were separate trials with different designs and participants. Subtracting their treatment averages is an indirect comparison, not the randomized effect of choosing one drug instead of the other. Their results provide background; SURMOUNT-5 directly addresses its specified head-to-head question. Neither result means everyone reaches the average. See why GLP-1 weight loss varies for the distinction between a population result and an individual response.

SURPASS-2 answered a different question in type 2 diabetes: tirzepatide versus semaglutide 1 mg weekly. It favored tirzepatide for glucose and weight outcomes, but that semaglutide dose and population are not the obesity comparison above. It should not be presented as the only or best available head-to-head evidence for weight management.4

Weight loss and tolerability are different decisions

Current Wegovy and Zepbound labels describe gastrointestinal adverse reactions and important warnings, including boxed thyroid C-cell tumor warnings and contraindications involving medullary thyroid carcinoma or MEN 2. Read the actual product information with your clinician rather than treating two drugs as sharing every warning or administration instruction.2, 6

Ask how your history, other medicines, symptoms and treatment response affect the choice. Establish who answers a clinical concern between refills, when follow-up occurs and how the practice handles treatment that is not tolerable. A low advertised price does not answer those questions. Our side-effects review and monitoring guide explain the evidence and the questions to bring to the practice.

Contraception is another reason to compare practical instructions alongside weight-loss results. Our birth-control guide separates the medicines and routes, rather than assuming every GLP-1 has the same interaction advice.

A compounded quote is a separate product question

FDA does not approve compounded drugs or review their safety, effectiveness and quality before marketing. The brand-product trials do not establish equivalence for an advertised compounded injection, sublingual liquid or tablet. The pharmacist and prescriber should explain the exact preparation, ingredients, concentration and directions.7

For approved brand products, Ozempic and Wegovy and Mounjaro and Zepbound have their own indication and product distinctions. For a compounded prescription, identify the actual dispensing pharmacy and discuss why that formulation is proposed. Do not choose an oral preparation on the assumption that an injection trial demonstrates its absorption or outcome.

Compare the cost of the plan you can actually continue

Request the selected medication, quantity, usable supply and required fees together. Separate an introductory price from renewal, a monthly payment from an annual equivalent and a care membership from medication. Ask what happens to the bill if the prescribed dose or supply changes.

Use the same time period for both services and leave unresolved costs explicit. Our six-month cost comparison and provider-selection checklist help organize that inquiry. If insurance is involved, confirm the specific product and your plan's conditions rather than assume one approval applies to every drug in the category.

A useful shortlist combines an appropriate prescription with an understandable ongoing bill and accessible clinical follow-up. A study average does not replace those parts of the decision.

Frequently asked questions

Is tirzepatide more effective than semaglutide for weight loss?

SURMOUNT-5 favored its tested tirzepatide injection regimens for average weight loss over 72 weeks in adults without diabetes. This is not a personal prediction or evidence comparing every current formulation and dose.

What is the difference in how they work?

Semaglutide is a GLP-1 receptor agonist; tirzepatide acts at GIP and GLP-1 receptors. That difference does not establish which prescription is appropriate for an individual.

Do brand-product trial results also establish compounded-drug effectiveness?

No. A compounded preparation is a separate product question. Discuss its exact formulation, instructions and rationale with the prescriber and dispensing pharmacist.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity.. New England Journal of Medicine. PubMed · PMID 33567185
  2. Novo Nordisk (2026). WEGOVY prescribing information: injection and tablet presentations, pharmacology and warnings. DailyMed, National Library of Medicine. Read source
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity.. New England Journal of Medicine. PubMed · PMID 35658024
  4. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.. New England Journal of Medicine. PubMed · PMID 34170647
  5. Aronne LJ, Horn DB, le Roux CW, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. New England Journal of Medicine. PubMed · PMID 40353578
  6. Eli Lilly and Company (2026). ZEPBOUND prescribing information: pharmacology, warnings and contraindications. DailyMed, National Library of Medicine. Read source
  7. U.S. Food and Drug Administration (2026). Understanding the Risks of Compounded Drugs. FDA. Read source

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.